Clinical trial
Study of Daclizumab in Patients With Chronic, Persistent Asthma
NCT00028288 · Facet Biotech, Industry · Completed
Key facts
| NCT number | NCT00028288 |
|---|---|
| Title | Study of Daclizumab in Patients With Chronic, Persistent Asthma |
| Official title | A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Daclizumab in Patients With Chronic, Persistent Asthma |
| Lead sponsor | Facet Biotech, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Daclizumab |
| Enrollment | 120 |
| Start date | Sep 1, 2001 |
| Primary completion | Dec 1, 2003 |
| Completion | Dec 1, 2003 |
| First posted | Dec 20, 2001 |
| Last update posted | Mar 13, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: